The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.
Pregabalin (Lyrica®) has been accepted for restricted use for the treatment of
peripheral neuropathic pain in adults. The review notes that evidence of efficacy is limited being based upon open-label, uncontrolled, non-randomised studies with small numbers of patients. As such pregabalin is only recommended in patients who have not benefited from or failed to tolerate conventional first and second line treatments.
[Update] This review also recommended that treatment is stopped if the patient has not shown sufficient benefit within 8 weeks of reaching the maximally tolerated therapeutic dose.
Thanks to Rita Shah for reminding me of this point.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« Elsevier apology||ALLHAT Findings Revisited »|